ATRIAL-NATRIURETIC-PEPTIDE AND CATECHOLAMINES IN OBSTRUCTIVE SLEEP-APNEA SYNDROME

被引:95
作者
BARUZZI, A
RIVA, R
CIRIGNOTTA, F
ZUCCONI, M
CAPPELLI, M
LUGARESI, E
机构
[1] Institute of Neurology, I-40123 Bologna
来源
SLEEP | 1991年 / 14卷 / 01期
关键词
CATECHOLAMINES; ATRIAL NATRIURETIC FACTOR; SLEEP APNEA; CONTINUOUS POSITIVE AIRWAY PRESSURE;
D O I
10.1093/sleep/14.1.83
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Nocturnal polyuria with repeated micturitions during the night is a clinically evident feature of obstructive sleep apnea syndrome (OSAS). These effects are reversed by continuous positive airway pressure (CPAP). There is some evidence that atrial natriuretic peptide (ANP) and catecholaminergic activity may be implicated in the pathogenesis of these symptoms. We studied these biochemical parameters in six patients with severe OSAS during two nights: the first (basal) in their normal conditions and the second during CPAP treatment. CPAP treatment reversed apnea episodes in all our patients. A significant (p < 0.035) reduction of nocturnal urine volume (from 902 +/- 297 to 447 +/- 130 ml; mean +/- SD), sodium excretion (from 150 +/- 33 to 89 +/- 35 mEq/12 h), noradrenaline excretion (from 95 +/- 101 to 52 +/- 16-mu-g/g creatinine), noradrenaline plasma concentrations (from 325 +/- 96 to 259 +/- 75 pg/ml), ANP plasma concentrations (from 35 +/- 20 to 19 +/- 5 pg/ml) was observed during the night under CPAP application. These data suggest that in OSAS patients the high ANP plasma concentration is responsible for the observed elevated diuresis and sodium excretion. These effects are rapidly reversible, as they are reversed during the first CPAP treated night.
引用
收藏
页码:83 / 86
页数:4
相关论文
共 19 条
[1]   ADRENERGIC HYPERACTIVITY AND CARDIAC ABNORMALITY IN PRIMARY DISORDERS OF SLEEP [J].
CLARK, RW ;
BOUDOULAS, H ;
SCHAAL, SF ;
SCHMIDT, HS .
NEUROLOGY, 1980, 30 (02) :113-119
[2]   URINARY CATECHOLAMINES BEFORE AND AFTER TRACHEOSTOMY IN PATIENTS WITH OBSTRUCTIVE SLEEP-APNEA AND HYPERTENSION [J].
FLETCHER, EC ;
MILLER, J ;
SCHAAF, JW ;
FLETCHER, JG .
SLEEP, 1987, 10 (01) :35-44
[3]   SLEEP APNEA SYNDROMES [J].
GUILLEMINAULT, C ;
TILKIAN, A ;
DEMENT, WC .
ANNUAL REVIEW OF MEDICINE, 1976, 27 :465-484
[4]  
JAMIESON AO, 1989, SLEEP RES, V19, P93
[5]   BLOOD-PRESSURE, CATECHOLAMINES, AND PANCREATIC-POLYPEPTIDE IN OBSTRUCTIVE SLEEP-APNEA WITH AND WITHOUT NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE (NCPAP) TREATMENT [J].
JENNUM, P ;
WILDSCHIODTZ, G ;
CHRISTENSEN, NJ ;
SCHWARTZ, T .
AMERICAN JOURNAL OF HYPERTENSION, 1989, 2 (11) :847-852
[6]   ATRIAL NATRIURETIC PEPTIDE RELEASE DURING SLEEP IN PATIENTS WITH OBSTRUCTIVE SLEEP-APNEA BEFORE AND DURING TREATMENT WITH NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE [J].
KRIEGER, J ;
LAKS, L ;
WILCOX, I ;
GRUNSTEIN, RR ;
COSTAS, LJV ;
MCDOUGALL, JG ;
SULLIVAN, CE .
CLINICAL SCIENCE, 1989, 77 (04) :407-411
[7]   URINARY-EXCRETION OF GUANOSINE 3'-5'-CYCLIC MONOPHOSPHATE DURING SLEEP IN OBSTRUCTIVE SLEEP-APNEA PATIENTS WITH AND WITHOUT NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT [J].
KRIEGER, J ;
SCHMIDT, M ;
SFORZA, E ;
LEHR, L ;
IMBS, JL ;
COUMAROS, G ;
KURTZ, D .
CLINICAL SCIENCE, 1989, 76 (01) :31-37
[8]  
KRIEGER J, 1988, ARCH INTERN MED, V148, P1337
[9]  
KRIEGER J, 1987, SLEEP RES, V16, P373
[10]  
LUGARESI E, 1983, B EUR PHYSIOPATH RES, V19, P590